A

Accuray

Robotics-assisted, image-guided radiotherapy for cancer

Reliability Systems Engineer

Full-Time
No salary listed
Senior
Bachelor's
Madison, WI, USA
In Person
Mechanical EngineeringMechanical Maintenance and Reliability Engineering
No H1B Sponsorship

About the job

Requirements
  • A bachelor's degree in Engineering or Physics and at least 5 years of design and development or reliability experience in a highly regulated industry.
  • Suitable work experience in a technically related field may be considered in lieu of formal education.
  • Basic understanding of control systems, electronics, and computer networks.
  • Hands-on experience with electronic test equipment and software.
  • Excellent troubleshooting and problem-solving skills.
  • Good verbal and written communication skills.
  • Proficient computer skills, including standard office software.
  • Ability to organize and coordinate technical tasks for other engineers.
  • Candidates must provide proof that they are authorized to work in the country they are applying to on a permanent basis without sponsorship.
Responsibilities
  • Develop user- and system-level product reliability requirements and allocate them to subsystem and component levels.
  • Provide guidance and implement strategies to verify reliability requirements for internal and sourced designs.
  • Translate user- and system-level objectives into system- and project-specific reliability plans.
  • Employ tools such as Failure Modes and Effects Analyses, usage definition, anticipated-stress evaluation, and field data analysis to identify and prioritize design risks and define mitigations.
  • Identify design analysis and non-test-based strategies, including de-rating, reliability prediction, modeling, and finite element analysis, to mitigate design risks and verify requirements.
  • Provide guidance on test strategies including reliability growth testing, HALT/step stress testing, environmental testing, and reliability demonstration testing.
  • Analyze and mentor other engineers in analysis techniques to characterize failure distributions and identify and mitigate dominant failure modes.
  • Track progress toward reliability objectives, facilitate regular reviews, and guide service, manufacturing, and quality organizations in achieving objectives for released products.
  • Mentor subsystem and component owners in identifying and executing beneficial reliability tools during product development.
  • Work with cross-functional teams to implement process changes, establish new processes when necessary, and promote reliability best practices.
  • Support functional and project managers in establishing and updating project milestones and schedules and evaluating engineering technologies and tools.
  • Work effectively with engineers, scientists, subcontractors, and contractors.
Desired Qualifications
  • An advanced technical degree or certification in the field of Reliability Engineering.
  • Experience with reliability analysis software.
  • Experience in application of statistical methods.
  • Knowledge of reliability tools such as Failure Modes and Effects Analysis, Weibull Analysis, Reliability Allocation and Prediction, De-rating, Root Cause Analysis, Ishikawa Diagrams, Pareto Analysis, Design of Experiments, and accelerated testing.
  • Experience in application of reliability methodologies across the product development cycle.
  • Experience in software-based test automation including Python.

About the company

Accuray provides cancer-care technology that uses robotics and image guidance to deliver precise, non-invasive radiation treatments. Its flagship CyberKnife system places a robotic arm around the patient to aim highly focused radiation beams at tumors anywhere in the body, performing radiosurgery without surgery. In 2011 it expanded its product line by acquiring TomoTherapy, adding a helical radiation therapy platform to its portfolio, broadening the ways clinicians can treat cancer. The company differentiates itself by combining robotics with real-time imaging to track tumors and adjust treatment in real time, and by offering a broader, multi-product radiation oncology system rather than a single device. Accuray’s goal is to provide effective, non-invasive cancer treatments to patients worldwide, growing its global installed base and advancing access to precise radiation therapy.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Madison, Wisconsin

Founded

1990

Get referred to Accuray

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2026 transformation delivered over $20 million in cost and margin improvements.
  • Q4 fiscal 2026 service revenue rose 6%, supporting margins despite product weakness.
  • September 2026 Samsung NeuroLogica collaboration expands CyberKnife imaging ambitions before commercial launch.

What critics are saying

  • Fiscal 2026 revenue fell 12% to $401.9 million; product revenue dropped 27%.
  • Accuray withdrew fiscal 2026 guidance in May 2026 after Middle East shipment delays.
  • TCW's covenant holiday ends December 2027; another sales slump risks lender-controlled restructuring.

What makes Accuray unique

  • CyberKnife delivers robotic radiosurgery with sub-millimeter precision across body tumors since 2001.
  • Fiscal 2026 services supplied 57% of revenue, creating recurring installed-base economics.
  • UW-Madison's 10-year collaboration and Samsung NeuroLogica partnerships deepen Accuray's technology ecosystem.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

3%

2 year growth

3%
Third News
Oct 6th, 2026
Accuray stockholders approve $60M financing deal and board expansion

Accuray Incorporated announced stockholders approved all proposals at its 6 October 2026 special meeting, advancing a strategic financing agreement with TCW Asset Management Company LLC, its primary lender and major shareholder. The July 2026 deal converts $40 million of term loan debt into convertible preferred stock and includes a $15 million equity investment from TCW. Accuray also gains access to a delayed draw term loan of up to $5 million and relief from certain financial covenants until 31 December 2027. Approved measures include issuing common stock under Nasdaq rules, increasing authorised shares, and implementing a reverse stock split with a ratio between 1-for-15 and 1-for-40. The company also announced governance enhancements and board expansion.

Market Chameleon
Sep 28th, 2026
Accuray (ARAY) highlights Samsung NeuroLogica volumetric imaging collaboration for CyberKnife as shares jump during market hours.

Accuray (ARAY) highlights Samsung NeuroLogica volumetric imaging collaboration for CyberKnife as shares jump during market hours. 28 September 2026, 9:55 AM The collaboration aims to bring more volumetric imaging information into the treatment room, but no product has been announced. Accuray Incorporated (NASDAQ:ARAY) said it has entered into agreements with Samsung HME America, Inc., dba NeuroLogica Corp. ("Samsung NeuroLogica") to pursue advanced volumetric imaging capabilities for the CyberKnife System. The announcement coincided with the American Society of Radiation Oncology (ASTRO) Annual Meeting in Boston, where the companies are highlighting their collaboration. Accuray framed the effort as part of a broader strategy of targeted partnerships - pairing Samsung NeuroLogica's experience in mobile CT and volumetric imaging with Accuray's strengths in precision treatment delivery, robotic radiosurgery, and motion management. Importantly for investors, the company said the work will proceed through phased development and evaluation and that no commercial product offering has been announced.

Business Insider
Sep 27th, 2026
Accuray, Samsung NeuroLogica advance volumetric imaging collaboration.

Accuray, Samsung NeuroLogica advance volumetric imaging collaboration. Sep. 27, 2026, 11:25 AM Accuray Incorporated (ARAY) announced that it had entered into agreements with Samsung HME America (SSNLF) to pursue advanced volumetric imaging capabilities for the CyberKnife System. The announcement coincides with the American Society of Radiation Oncology, ASTRO, Annual Meeting in Boston, Massachusetts, where the companies are highlighting their collaboration. The collaboration represents another example of Accuray's strategy to address customer priorities through targeted partnerships that bring together complementary expertise. Published first on TheFly - the ultimate source for real-time, market-moving breaking financial news. Try Now>> Read More on ARAY:

Yahoo Finance
Aug 20th, 2026
Accuray secures $55M financing, cuts costs by $20M amid China headwinds and tariff uncertainty

Accuray Incorporated reported fiscal 2026 results, describing the year as foundational for streamlining operations and reducing costs. Geopolitical tensions and tariff uncertainty in China contributed to approximately $58 million in product revenue decline. The company achieved $20 million in cost and margin improvements, exceeding its initial $12 million target. Service revenue grew 6% in Q4, driven by strategic pricing and an expanding installed base. Accuray is pivoting to a partner-centric model, using nonbinding letters of intent with Samsung Medison and Research Laboratories to accelerate innovation. The company completed a restructuring transaction with TCW Asset Management, converting $40 million of debt into preferred equity. Management is not providing fiscal 2027 guidance due to geopolitical uncertainty. The company expects approximately $15 million in additional annualised cost improvements and has secured a covenant holiday through December 2027.

Yahoo Finance
Aug 20th, 2026
Accuray posts $402M revenue, achieves $20M cost savings amid 12% annual decline

Accuray reported Q4 2026 net revenue of $100.9 million, down 21% year-over-year, with full-year revenue at $402 million, down 12%. Product revenue fell 42% in Q4 to $40.8 million, whilst service revenue rose 6% to $60.1 million. The medical device company exceeded its transformation cost-saving target, achieving over $20 million in savings versus a $12 million goal. Q4 gross margin improved to 34.8% from 30.6% in the prior year. Accuray strengthened its balance sheet through a transaction with TCW, including debt conversion and a $15 million cash investment. The company ended Q4 with $48.8 million in cash and $313 million in order backlog. Full-year adjusted EBITDA was $10.6 million, down from $28.3 million in the prior year.